Global Gastroparesis Drugs Market to Grow at a CAGR of 3.5% by 2021 – Fast Track Approvals & Acquisitions to Change the Phase of the Market – Research and Markets

DUBLIN, May 15, 2017 /PRNewswire/ —

Research and Markets has announced the addition of the “Global Gastroparesis Drugs Market 2017-2021” report to their offering.

The global gastroparesis drugs market to grow at a CAGR of 3.54% during the period 2017-2021.

The report, Global Gastroparesis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in market is fast track approvals and acquisitions to change the phase of the market. High unmet needs in the treatment of gastroparesis have led the fast track approvals of certain drugs. For example, in 2016, Theravance Biopharma received the US FDA fast track designation for velusetrag for idiopathic and diabetic gastroparesis. At present, the drug is in Phase II clinical stage. The fast track approval by the US FDA is done to facilitate the need to treat serious conditions associated with gastroparesis.

According to the report, one driver in market is rising gastric surgeries fueling the prevalence rate of post-surgical gastroparesis. Post-surgical gastroparesis is the third most common type of the gastroparesis after idiopathic and diabetic gastroparesis. Gastric surgeries include surgeries that are done to digestive parts of the bodies such as the esophagus, duodenum, and stomach. During the gastric surgery, there is a high chance that the vagus nerves get injured. Injury to these nerves is the major cause of gastroparesis. Some of the common types of gastric surgeries are gastric bypass surgeries and bariatric surgeries. Rising obesity is a major reason for these surgeries. As one of the major aims of these surgeries is weight loss. Vagus nerve damage is one of the major complications associated with gastric bypass. Sleeve gastrectomy has also seen to alter the gut-brain communication.

Key vendors

  • Cadila Pharmaceuticals
  • GlaxoSmithKline
  • Johnson & Johnson
  • Valeant

Other prominent vendors

  • Evoke Pharma
  • Teva Pharmaceutical Industries
  • Theravance Biopharma

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Market landscape

PART 07: Pipeline landscape

PART 08: Market segmentation by disease type

PART 09: Market segmentation by drug class

PART 10: Geographical segmentation

PART 11: Decision framework

PART 12: Drivers and challenges

PART 13: Market trends

PART 14: Vendor landscape

PART 15: Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:—fast-track-approvals–acquisitions-to-change-the-phase-of-the-market—research-and-markets-300456774.html

SOURCE Research and Markets

Related Links